Eicosanoids in Cancer: Prostaglandin E
EP4
cancer
immunotherapy
microenvironment
prostaglandin E2
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
01
2020
accepted:
19
05
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
The cyclooxygenase-2 (COX-2) enzyme is frequently overexpressed in epithelial malignancies including those of the breast, prostate, lung, kidney, ovary, and liver and elevated expression is associated with worse outcomes. COX-2 catalyzes the metabolism of arachidonic acid to prostaglandins. The COX-2 product prostaglandin E
Identifiants
pubmed: 32547404
doi: 10.3389/fphar.2020.00819
pmc: PMC7273839
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
819Subventions
Organisme : BLRD VA
ID : I01 BX000169
Pays : United States
Informations de copyright
Copyright © 2020 Ching, Reader and Fulton.
Références
Cancer Res. 2007 May 1;67(9):4507-13
pubmed: 17483367
BMC Cancer. 2017 Jan 5;17(1):11
pubmed: 28056899
Oncogene. 2017 Apr 20;36(16):2319-2327
pubmed: 27869171
J Immunother. 2012 Feb-Mar;35(2):179-88
pubmed: 22306906
Sci Rep. 2016 Apr 01;6:23824
pubmed: 27032536
FEBS Lett. 2007 Feb 6;581(3):565-71
pubmed: 17254571
EBioMedicine. 2019 Nov;49:172-188
pubmed: 31662289
Cancer Res. 2006 Mar 15;66(6):2923-7
pubmed: 16540639
Cell Rep. 2017 Oct 3;21(1):154-167
pubmed: 28978469
Oncoimmunology. 2013 Jan 1;2(1):e22647
pubmed: 23482441
Int J Cancer. 2018 Sep 15;143(6):1440-1455
pubmed: 29658109
Oncogene. 2007 May 10;26(21):3006-19
pubmed: 17130837
Int J Mol Sci. 2019 Dec 11;20(24):
pubmed: 31835815
J Lab Clin Med. 2002 Aug;140(2):92-102
pubmed: 12228765
Biochem Biophys Res Commun. 2016 Sep 9;478(1):154-161
pubmed: 27450806
Am J Cancer Res. 2015 Oct 15;5(11):3325-38
pubmed: 26807314
Cancer Sci. 2020 Jan;111(1):160-174
pubmed: 31755615
Br J Cancer. 2018 Jan;118(2):213-223
pubmed: 29123257
Cancer Sci. 2014 Sep;105(9):1142-51
pubmed: 24981602
Cancers (Basel). 2019 Oct 18;11(10):
pubmed: 31635323
J Biol Chem. 2015 Dec 11;290(50):29781-93
pubmed: 26475855
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1297-1304
pubmed: 30053598
Biochem Biophys Res Commun. 2019 Aug 20;516(2):388-396
pubmed: 31217077
Front Immunol. 2018 Aug 09;9:1859
pubmed: 30140269
Front Immunol. 2020 Mar 10;11:324
pubmed: 32210957
Int J Biochem Cell Biol. 2019 Nov;116:105610
pubmed: 31518663
Cancer Res. 2006 Oct 1;66(19):9665-72
pubmed: 17018624
Breast Cancer Res Treat. 2009 Sep;117(2):235-42
pubmed: 18792778
Clin Cancer Res. 2014 Aug 1;20(15):4096-106
pubmed: 24907113
Eur J Cell Biol. 2017 Mar;96(2):218-226
pubmed: 28094049
Prostate. 2019 Jul;79(10):1133-1146
pubmed: 31050003
Carcinogenesis. 2009 Jan;30(1):141-9
pubmed: 18849297
Mol Cancer Res. 2010 Apr;8(4):569-77
pubmed: 20353998
J Exp Clin Cancer Res. 2019 May 29;38(1):228
pubmed: 31142342
BMB Rep. 2018 Oct;51(10):532-537
pubmed: 30269738
Biochem Pharmacol. 2010 Sep 15;80(6):838-45
pubmed: 20470757
Mol Med Rep. 2018 Mar;17(3):4702-4712
pubmed: 29328471
Cancer Metastasis Rev. 2011 Dec;30(3-4):449-63
pubmed: 22002714
Cancer Res. 2010 Feb 15;70(4):1606-15
pubmed: 20145136
Int J Mol Sci. 2018 Mar 29;19(4):
pubmed: 29596308
Breast Cancer Res. 2013;15(5):R75
pubmed: 24004819
PLoS One. 2015 Feb 23;10(2):e0115855
pubmed: 25706647
Br J Pharmacol. 2016 Nov;173(21):3099-3109
pubmed: 27460634
Mol Oncol. 2014 Dec;8(8):1626-39
pubmed: 25034079
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Oncotarget. 2015 Mar 10;6(7):4829-44
pubmed: 25638159
Cancer Lett. 2017 Apr 10;391:50-58
pubmed: 28104442
Breast Cancer Res Treat. 2014 Jan;143(1):19-31
pubmed: 24281828
Oncoimmunology. 2017 Jun 28;6(8):e1338239
pubmed: 28920002
Sci Rep. 2019 Mar 20;9(1):4954
pubmed: 30894570